Morgan Stanley restated their underweight rating on shares of Illumina, Inc. (NASDAQ:ILMN) in a research note published on Monday morning. Morgan Stanley currently has a $115.00 target price on the life sciences company’s stock, up from their prior target price of $108.00.
Several other brokerages have also commented on ILMN. Deutsche Bank AG restated a hold rating and set a $175.00 price target (up from $165.00) on shares of Illumina in a research note on Saturday, April 29th. Cowen and Company restated an outperform rating and set a $200.00 price target on shares of Illumina in a research note on Wednesday, April 26th. Cantor Fitzgerald upped their price target on Illumina from $155.00 to $170.00 and gave the stock a neutral rating in a research note on Wednesday, April 26th. Vetr lowered Illumina from a strong-buy rating to a buy rating and set a $195.67 price target for the company. in a research note on Tuesday, April 25th. Finally, Piper Jaffray Companies restated an overweight rating and set a $187.00 price target (up from $170.00) on shares of Illumina in a research note on Friday, April 14th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $164.97.
Shares of Illumina (NASDAQ:ILMN) traded up 0.55% during mid-day trading on Monday, hitting $176.86. The company had a trading volume of 432,225 shares. The company has a market cap of $25.82 billion, a PE ratio of 35.79 and a beta of 0.79. The firm has a 50-day moving average of $178.41 and a 200-day moving average of $156.53. Illumina has a 12 month low of $119.37 and a 12 month high of $189.48.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.64. The firm had revenue of $598 million during the quarter, compared to analyst estimates of $590.51 million. Illumina had a return on equity of 22.89% and a net margin of 19.31%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.71 earnings per share. On average, analysts expect that Illumina will post $3.63 EPS for the current year.
In related news, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $187.07, for a total value of $300,995.63. Following the sale, the senior vice president now owns 10,936 shares of the company’s stock, valued at approximately $2,045,797.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director A Blaine Bowman sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 12th. The stock was sold at an average price of $172.72, for a total value of $518,160.00. Following the completion of the sale, the director now directly owns 18,704 shares in the company, valued at approximately $3,230,554.88. The disclosure for this sale can be found here. In the last three months, insiders sold 35,521 shares of company stock worth $6,465,772. Company insiders own 1.60% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Advocacy Wealth Management Services LLC acquired a new stake in Illumina during the first quarter valued at approximately $102,000. Advisory Services Network LLC acquired a new stake in Illumina during the first quarter valued at approximately $117,000. Gemmer Asset Management LLC boosted its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares in the last quarter. Probity Advisors Inc. acquired a new stake in Illumina during the first quarter valued at approximately $204,000. Finally, Bronfman E.L. Rothschild L.P. boosted its stake in Illumina by 3.6% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 1,198 shares of the life sciences company’s stock valued at $204,000 after buying an additional 42 shares in the last quarter. 92.79% of the stock is currently owned by institutional investors and hedge funds.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/morgan-stanley-reaffirms-underweight-rating-for-illumina-inc-ilmn/1835992.html
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.